Vestibular Schwannoma (Acoustic Neuroma) – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Vestibular Schwannoma (Acoustic Neuroma) – Drugs In Development, 2024 report and make more profitable business decisions.
Vestibular schwannoma is a benign, slow-growing tumor that develops from the balance and hearing nerves. It is also called an acoustic neuroma/neurinoma/neurilemma and is mainly caused by overproduction of Schwann cells. It affects the hearing and balance nerves, causing unilateral or asymmetric hearing loss, tinnitus, and dizziness/loss of balance. It can be diagnosed by thorough ear examination and hearing and balance testing with the help of an audiogram, electronystagmography, and the auditory brainstem response (ABR) test. MRI scans can also help in early detection, determining location and size of acoustic neuroma in planning microsurgical removal. There are three options for managing a vestibular schwannoma: surgical removal, radiation, and observation. Alternative to surgical techniques, radiosurgery/radiotherapy (gamma knife) can be used to reduce the size of tumors.
The Vestibular Schwannoma (Acoustic Neuroma) drugs in development market research report provide comprehensive information on the therapeutics under development for Vestibular Schwannoma (Acoustic Neuroma), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Vestibular Schwannoma (Acoustic Neuroma) and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Vestibular Schwannoma (Acoustic Neuroma) | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 6 molecules, with 5 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Vestibular Schwannoma (Acoustic Neuroma) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Vestibular Schwannoma (Acoustic Neuroma) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Vestibular Schwannoma (Acoustic Neuroma) treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Akouos IncAstraZeneca Plc
Massachusetts Eye and Ear Infirmary
Millennium Pharmaceuticals Inc
Novartis AG
Recursion Pharmaceuticals Inc
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Vestibular Schwannoma (Acoustic Neuroma) reports